Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study
Authors
Keywords
-
Journal
ANNALS OF THE RHEUMATIC DISEASES
Volume 73, Issue 9, Pages 1607-1615
Publisher
BMJ
Online
2014-03-19
DOI
10.1136/annrheumdis-2013-204760
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- OP0025 Results from a multicenter, international, randomized, double-blind, placebo-controlled, phase 2 study of sirukumab, a human anti-IL-6 monoclonal antibody, in patients with active rheumatoid arthritis despite methotrexate therapy
- (2014) B. Hsu et al. ANNALS OF THE RHEUMATIC DISEASES
- Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy
- (2014) Norihiro Nishimoto et al. Modern Rheumatology
- Clinical evaluation of tocilizumab for patients with active rheumatoid arthritis refractory to anti-TNF biologics: tocilizumab in combination with methotrexate
- (2014) Yasuharu Nakashima et al. Modern Rheumatology
- Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI study
- (2014) Jun Hashimoto et al. Modern Rheumatology
- Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial
- (2013) Cem Gabay et al. LANCET
- A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate
- (2012) P Mease et al. ANNALS OF THE RHEUMATIC DISEASES
- Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)
- (2012) Maxime Dougados et al. ANNALS OF THE RHEUMATIC DISEASES
- Whole-Molecule Antibody Engineering: Generation of a High-Affinity Anti-IL-6 Antibody with Extended Pharmacokinetics
- (2011) Donna K. Finch et al. JOURNAL OF MOLECULAR BIOLOGY
- Increased rheumatoid factor interference observed during immunogenicity assessment of an Fc-engineered therapeutic antibody
- (2011) James Araujo et al. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
- The role of synovial fluid markers of catabolism and anabolism in osteoarthritis, rheumatoid arthritis and asymptomatic organ donors
- (2011) Rediet Kokebie et al. ARTHRITIS RESEARCH & THERAPY
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
- (2010) J. S. Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative
- (2010) Daniel Aletaha et al. ARTHRITIS AND RHEUMATISM
- Rheumatoid factor interference in immunogenicity assays for human monoclonal antibody therapeutics
- (2010) Suzanna Tatarewicz et al. JOURNAL OF IMMUNOLOGICAL METHODS
- The role of Interleukin 6 in the pathophysiology of rheumatoid arthritis
- (2010) Srinivasan Srirangan et al. Therapeutic Advances in Musculoskeletal Disease
- TNF-α Antagonist Survival Rate in a Cohort of Rheumatoid Arthritis Patients Observed under Conditions of Standard Clinical Practice
- (2009) Antonio Marchesoni et al. Annals of the New York Academy of Sciences
- Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review
- (2009) Andrea Rubbert-Roth et al. ARTHRITIS RESEARCH & THERAPY
- IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
- (2008) P. Emery et al. ANNALS OF THE RHEUMATIC DISEASES
- Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study
- (2008) Mark C. Genovese et al. ARTHRITIS AND RHEUMATISM
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started